diazepam has been researched along with piroxicam in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.08) | 18.7374 |
| 1990's | 4 (8.16) | 18.2507 |
| 2000's | 8 (16.33) | 29.6817 |
| 2010's | 34 (69.39) | 24.3611 |
| 2020's | 1 (2.04) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Carrupt, PA; Martel, S; Ottaviani, G | 1 |
| Baert, B; Beetens, J; Bodé, S; De Spiegeleer, B; Deconinck, E; Lambert, J; Slegers, G; Slodicka, M; Stoppie, P; Van Gele, M; Vander Heyden, Y | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Avdeef, A; Tam, KY | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Buttar, D; Colclough, N; Gerhardt, S; MacFaul, PA; Maskos, K; Phillips, SD; Plowright, A; Steinbacher, S; Steuber, H; Tam, K; Whittamore, P | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Barber, S; Dew, TP; Farrell, TL; Poquet, L; Williamson, G | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Deng, Y; Li, Y; Liu, Q; Qiang, X; Sang, Z; Tan, Z; Xiao, G | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xiao, G | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Yang, X; Zheng, Y | 1 |
| Ai, J; Deng, Y; Li, Y; Liu, Q; Luo, L; Qiang, X; Tan, Z; Xiao, G; Yang, X | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Xu, R; Yang, X; Zheng, Y | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, X | 1 |
| Bai, P; Leng, C; Li, X; Liu, W; Ma, Q; Pan, W; Sang, Z; Tan, Z; Wang, K; Xu, Q; Yang, Y; Yu, L | 1 |
| Liu, W; Ma, Q; Pan, W; Sang, Z; Wang, K; Yu, L | 1 |
| Han, X; Liu, W; Ma, Q; Sang, Z; Wang, H; Wang, K; Ye, M; Yu, L | 2 |
| Dong, SN; Gong, Q; Li, J; Li, XK; Liu, WW; Mao, F; Tang, Y; Wang, H; Wang, TD; Xu, YX; Zhang, HY; Zhu, J | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Xu, R; Yang, J; Zhang, X | 1 |
| Deng, Y; Li, Y; Liu, H; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, Z; Zhang, X; Zheng, Y | 1 |
| Gong, Q; Li, J; Li, X; Liu, W; Mao, F; Qiu, X; Wang, H; Wang, W; Xu, Y; Zhang, H; Zhang, J; Zhu, J | 1 |
| An, Q; Deng, Y; Liu, P; Luo, Y; Sang, Z; Tang, Y; Wang, T; Yang, T; Yang, Y; Zhang, T | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Tian, C; Yang, Z | 1 |
| Deng, Y; He, Y; Li, W; Liu, H; Qiang, X; Song, Q; Tan, Z; Ye, C | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K; Zhang, P | 1 |
| Fan, X; Liu, W; Sang, Z; Shi, J; Wang, K; Yang, D; Zhang, P; Zhang, Z; Zhu, G | 1 |
| Bai, P; Cheng, X; Cheng, Y; Lu, X; Sang, Z; Shi, J; Wang, K; Yang, J; Zhang, P; Zhang, Q; Zheng, C | 1 |
| Bajusz, D; Balogh, GT; Dargó, G; Müller, J; Simon, K | 1 |
| Antimisiaris, SG; Koupparis, MA; Macheras, PE | 1 |
| Guentert, TW; Stebler, T | 1 |
| Matsuyama, K; Perrin, JH; Sen, AC | 1 |
| Trnavská, Z; Trnavský, K | 1 |
| Brée, F; Nguyen, P; Simonyi, M; Steiner, A; Testa, B; Tillement, JP; Urien, S; Vallat-Molliet, C; Visy, J | 1 |
| Prodanova, K; Rakovska, R; Russeva, V; Zhivkova, Z | 1 |
| Navarte, DA; Rosset-Llobet, J | 1 |
1 review(s) available for diazepam and piroxicam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
48 other study(ies) available for diazepam and piroxicam
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
Topics: Humans; Membranes, Artificial; Models, Biological; Models, Molecular; Octanols; Permeability; Pharmaceutical Preparations; Skin Absorption; Water | 2007 |
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
Topics: Anti-Inflammatory Agents; Cell Membrane Permeability; Cluster Analysis; Drug Evaluation, Preclinical; Humans; Models, Biological; Predictive Value of Tests; Quantitative Structure-Activity Relationship; Regression Analysis; Skin; Skin Absorption | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
Topics: Binding Sites; Crystallography, X-Ray; Drug Interactions; Humans; Pharmaceutical Preparations; Protein Binding; Protein Structure, Tertiary; Serum Albumin; Spectrometry, Fluorescence | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Cinnamates; Enterocytes; Humans; Hydrophobic and Hydrophilic Interactions; Intestinal Absorption; Kinetics; Models, Biological; Molecular Conformation; Osmolar Concentration; Phenols | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Blood-Brain Barrier; Butyrylcholinesterase; Carbamates; Cell Line; Chelating Agents; Cholinesterase Inhibitors; Cognition; Glucuronates; Humans; Mice; Molecular Docking Simulation; Neuroprotective Agents; Rats | 2015 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; Chelating Agents; Copper; Humans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Swine | 2016 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Isoflavones; Mannich Bases; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Mannich Bases; Neuroprotective Agents; PC12 Cells; Rats | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Rivastigmine; Structure-Activity Relationship; Swine | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Blood-Brain Barrier; Edaravone; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Protein Structure, Tertiary | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors; Humans; Kinetics; Models, Molecular; Monoamine Oxidase Inhibitors; Thioxanthenes; Xanthones | 2017 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Coumaric Acids; Drug Design; Eels; Humans; Memory Disorders; Mice; PC12 Cells; Rats | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quinolines; Swine | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Inhibitory Concentration 50; Kinetics; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phthalimides; Protein Structure, Tertiary; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Drug Design; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Neuroprotective Agents; PC12 Cells; Permeability; Phenols; Piperazines; Protein Structure, Tertiary; Rats; Structure-Activity Relationship | 2017 |
Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognitive Dysfunction; Dose-Response Relationship, Drug; Drug Discovery; Humans; Imidazoles; Mice; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Propylamines; Pyrimidines; Rats; Scopolamine; Structure-Activity Relationship; Thiourea | 2018 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Survival; Chalcones; Chelating Agents; Copper; Drug Design; Flurbiprofen; Humans; Lipopolysaccharides; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nitric Oxide; Peptide Fragments; Recombinant Proteins; Structure-Activity Relationship | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Permeability; Protein Aggregates; Recombinant Proteins; Structure-Activity Relationship; Thiazoles | 2018 |
Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Depression; Drug Design; Ligands; Mice; Permeability; Serotonin 5-HT1 Receptor Agonists; Structure-Activity Relationship; Tacrine; Vilazodone Hydrochloride | 2018 |
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
Topics: Antineoplastic Agents; Antitubercular Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyrroles; Quinoxalines; Structure-Activity Relationship | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Butyrylcholinesterase; Chelating Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Molecular; Molecular Structure; Peptide Fragments; Phthalimides; Protein Aggregates; Structure-Activity Relationship | 2018 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cholinesterase Inhibitors; Drug Design; Drug Discovery; Electrophorus; Flurbiprofen; Humans; Mannich Bases; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Rats; Swine | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Eels; Female; Horses; Humans; Male; Maze Learning; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase Inhibitors; Drug Design; Eels; Horses; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Peptide Fragments; Protein Aggregates | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Development; Humans; Kinetics; Models, Molecular; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Transport; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Chelating Agents; Cholinesterase Inhibitors; Coordination Complexes; Copper; Drug Design; Female; Humans; Male; Memory Disorders; Mice; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Protein Binding; Scopolamine; Structure-Activity Relationship | 2019 |
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
Topics: Binding Sites; Chemistry, Pharmaceutical; Drug Design; Humans; Hydrogen-Ion Concentration; Molecular Docking Simulation; Pharmaceutical Preparations; Protein Binding; Serum Albumin, Human; Spectrophotometry, Ultraviolet; Titrimetry | 2020 |
Drug binding and solubility in milk.
Topics: Animals; Cattle; Diazepam; Dicumarol; Dose-Response Relationship, Drug; Frozen Foods; Griseofulvin; Indomethacin; Kinetics; Milk; Nitrofurantoin; Pharmaceutical Preparations; Piroxicam; Prednisolone; Solubility; Temperature; Thermodynamics | 1990 |
Binding of drugs in milk: the role of casein in milk protein binding.
Topics: Albumins; Animals; Benzodiazepines; Caseins; Cattle; Chemical Phenomena; Chemistry, Physical; Diazepam; Dogs; Goats; Horses; Humans; Milk; Milk, Human; Pharmaceutical Preparations; Piroxicam; Protein Binding; Rabbits; Sheep; Species Specificity | 1990 |
Binding of piroxicam to human serum albumin: effect of piroxicam on warfarin and diazepam binding.
Topics: Diazepam; Drug Interactions; Humans; Piroxicam; Protein Binding; Serum Albumin; Warfarin | 1987 |
Plasma protein binding and interaction studies with piroxicam.
Topics: Anti-Inflammatory Agents; Bilirubin; Blood Proteins; Diazepam; Humans; In Vitro Techniques; Palmitic Acid; Palmitic Acids; Piroxicam; Protein Binding; Salicylates; Serum Albumin; Thiazines; Warfarin | 1984 |
Human serum albumin conformational changes as induced by tenoxicam and modified by simultaneous diazepam binding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chromatography, Affinity; Dialysis; Diazepam; Humans; Hydrogen-Ion Concentration; Kinetics; Piroxicam; Protein Binding; Protein Conformation; Serum Albumin | 1993 |
Protein binding of piroxicam studied by means of affinity chromatography and circular dichroism.
Topics: Binding Sites; Chromatography, High Pressure Liquid; Circular Dichroism; Diazepam; Humans; In Vitro Techniques; Phenylbutazone; Piroxicam; Serum Albumin | 1999 |
Safety of subcutaneous microinjections (mesotherapy) in musicians.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Diazepam; Female; Humans; Injections, Subcutaneous; Male; Mesotherapy; Middle Aged; Muscle Relaxants, Central; Musculoskeletal Diseases; Music; Occupational Diseases; Pain; Pain Measurement; Pentoxifylline; Piroxicam; Pyrrolidines; Surveys and Questionnaires; Vasodilator Agents; Young Adult | 2011 |